Page 8 - NowAware_Press Kit

Seeing REaD
A testing capacity increase of many orders of magnitude: The REaD platform can provide millions of detection results per week using a multi-mode microplate reader, a standard piece of equipment present in most labs across the country.
NOWAWARE COVID-19 TESTING CAPACITY
# of Wells
# of Tests/hr 100 CLIA Labs with one Reader per Reader Tests/Day Tests/Week
96 1,920
384 3,840
1,536 6,144
4,608,000 9,216,000 14,745,000
32,256,000 64,512,000 103,219,200
ASSUMPTIONS:
1 minute for 96-well plate whereas actual read time is only 20 seconds
2 minutes for 384-well plate 5 minutes for 1,536-well plate
Footnote: Based on the following conservative time to run test which
is sample read cycle time for each microplate density.
A reliable test for today and tomorrow:
The REaD test results have confirmed that our engineered peptide substrate can identify the main proteinase (3CLpro) and the papain- like protease (PLpro) produced in the infected host cell of COVID-19 that is analogous to its cousin coronavirus’ SARS and MERS. This makes our test highly valuable in identifying the presence of this virus even before the onset of symptoms.
A test that comes with a mobile app (Coming Soon): REaD will be accompanied by a mobile NowAware App that will allow lab technicians to process each patient in less than 1 to 2 minutes. The Patient, The App and The Lab Technician will work together to facilitate the process: The patient collects their sample with the tongue brush and sends it to the lab. The lab technician processes the sample to test and analyze the results. The app provides a platform for the technician to upload the results for the patient to view. The entire sample collection workflow is quick and 100% contactless between the staff and the patient. This approach can dramatically reduce the utilization of Personal Protective Equipment (PPE) and infection risk to the staff.
A test that can detect strong fluorescent signal: RT-PCR detection is unable to do this, making the REaD test valuable in picking up contaminated cells where other methods are consistently failing short.
A test that can measure RT-PCR rate of false negative: The REaD testing platform generates clear differences in fluorescence intensity. Positive samples are indicated by a distinct, consistent, increasing intensity over time, whereas negative samples are indicated by no visible fluoresence.
A test that allows self-sample collection that is safe and easy: The sample capture for the REaD test requires the patient to painlessly rub a brush against their tongue for 10 seconds in order to collect a sufficient number of infected cells. This procedure does not produce aerosolization of the virus, which has raised concern to the FDA and CDC while resulting in infection to healthcare workers.
A test that can detect infection before RT-PCR: The REaD test utilizes tongue brush collection methodology because human epithelia cells in mouth have an abundance of ACE2 receptors. This provides a rich source of early COVID-19 infected cells, enabling detection at the earliest point of infection time possible.
Copyright © 2020. Bambu Vault, LLC and NowAware Inc. All Rights Reserved. Proprietary and Confidential.
833-467-8363